Clinical efficacy of reboxetine in major depression

Journal of Clinical Psychiatry

Volumn 61, Issue SUPPL. 10, 2000, Pages 31-38

  Schatzberg, Alan F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; DESIPRAMINE; FLUOXETINE; MIRTAZAPINE; NEFAZODONE; REBOXETINE; VENLAFAXINE;

ANTICHOLINERGIC EFFECT; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW; URINARY DYSFUNCTION;

ADRENERGIC UPTAKE INHIBITORS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CONTROLLED CLINICAL TRIALS; DEPRESSIVE DISORDER; FLUOXETINE; HUMANS; IMIPRAMINE; MORPHOLINES; NOREPINEPHRINE; PANIC DISORDER; PLACEBOS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0033942654     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Roose SP. Tolerability and patient compliance. J Clin Psychiatry 1999;60 (suppl 17):14-17
2. Montgomery SA. The place of reboxetine in antidepressant therapy [chairman's overview]. J Clin Psychiatry 1998;59(suppl 14):26-29
3. Montgomery SA, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994;9:47-53
4. Montgomery SA, Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int Clin Psychopharmacol 1995;9(suppl 4):33-40
5. Anderson IM. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998;7 (suppl 1):11-17
6. Brunello N, Racagni G. Rationale for the development of noradrenaline reuptake inhibitors. Hum Psychopharmacol 1998;13:S13-S19
7. Roose SP. Tolerability and patient compliance. J Clin Psychiatry 1999;60 (suppl 17):14-17
8. Massana J. Reboxetine versus fluoxetine: an overview of efficacy and tolerability. J Clin Psychiatry 1998;59(suppl 14):8-10
9. Massana J, Moller HJ, Burrows GD, et al. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73-80
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition. Washington, DC: American Psychiatric Association; 1980
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987
12. Montgomery SA Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 1997;11(suppl 4):S9-S15
13. Ban TA, Gaszner P, Aguglia E, et al. Clinical efficacy of reboxetine: a comparative study with desipramine - with methodological considerations. Hum Psychopharmacol 1998;13:S29-S39
14. Versiani M, Amin M, Chouinard G. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol 2000;20:28-34
15. Quitkin FM, Rabkin JG, Gerald J, et al. Validity of clinical trials of antidepressants. Am J Psychiatry 2000;157:327-337
16. Massana J, Möller H-J, on behalf of the Reboxetine Study Group. In severe depression, reboxetine is as effective as imipramine and more effective than fluoxetine. Presented at the 11th annual meeting of the European College of Neuropsychopharmacology; November 1-5, 1998; Paris, France
17. Bosc M, Dubini A, Polin V. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. Eur Neuropsychopharmacol 1997;7(suppl 1):S57-S70
18. Dubini A, Bosc M, Polin V. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J Psychopharmacol 1997;11(suppl 4):S17-S23
19. Leader JB, Klein DN. Social adjustment in dysthymia, double depression, and episodic major depression. J Affect Disord 1996;37:91-101
20. Kasper S. From symptoms to social functioning: differential effects of antidepressant therapy. Int Clin Psychopharmacol 1999;14(suppl 1):S27-S31
21. Hays RD, Wells KB, Sherbourne CD. Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch Gen Psychiatry 1995;52:11-19
22. Dubini A, Bosc M, Polin V. Do noradrenaline and serotonin differentially affect social motivation and behaviour? Eur Neuropsychopharmacol 1997; 7(suppl 1):S49-S55
23. Burns RA, Lock T, Edwards DR, et al. Predictors of response to amine-specific antidepressants. J Affect Disord 1995;35:97-106
24. Montgomery SA, James D, Montgomery DB. Pharmacologic specificity is not the same as clinical selectivity. In: Dahl SG, ed. Clinical Pharmacology in Psychiatry. Berlin, Germany: Springer Verlag; 1987:179-183
25. Nystrom C, Hallstrom T. Double-blind comparison between a serotonin and a noradrenaline reuptake blocker in the treatment of depressed outpatients. Acta Psychiatr Scand 1985;78:384-390
26. Keller MB, Klerman GL, Lavori PW, et al. Long-term outcome of episodes of major depression: clinical and public health significance. JAMA 1984; 252:788-792
27. Montgomery SA. Antidepressants in long-term treatment. Ann Rev Med 1994;45:447-457
28. Impact of neuropharmacology in the 1990s: strategies for the therapy of depressive illness. Task Force of the Collegium Internationale Neuro Psychopharmacologicum (CINP). Eur Neuropsychopharmacol 1993;3: 153-156
29. Hirschfeld RMA. Guidelines for the long-term treatment of depression. J Clin Psychiatry 1994;55(12, suppl):61-69
30. Hirschfeld RM. Long-term drug treatment of unipolar depression. Int Clin Psychopharmacol 1996:11:211-217
31. Keller MB, Boland RJ. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry 1998:44:348-360
32. Angst J. How recurrent and predictable is depressive illness? In: Montgomery SA, Rouillon F, eds. Long-Term Treatment of Depression. Chichester, England: Wiley Press; 1992:1-14
33. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 1999;156:1000-1006
34. Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998:55:1128-1132
35. Kasper S. The rationale for long-term antidepressant therapy. Int Clin Psychopharmacol 1993:8:225-235
36. Versiani M, Mehilane L, Gaszner P, et al. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry 1999;60:400-406
37. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur Neuropsychopharmacol 1997;7(suppl 1):S37-S47
38. Katona C, Bercoff E, Chiu E, et al. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial. J Affect Disord 1999;55:203-213